--- title: "Serina Therapeutics (SER) news: going concern and offering" url: "https://aibio.space/companies/serina-therapeutics/" publisher: "aibio.space (Biotech Investor Relations News)" summary: "SER going concern and offering news: Serina Therapeutics sets up $13,270,500 at-the-market share sales program. Serina Therapeutics, Inc." --- SER Serina Therapeutics, Inc. AMEX · United States # Serina Therapeutics (SER) news SER going concern and offering news Financings · 2025-04-28 ## [Serina Therapeutics sets up $13,270,500 at-the-market share sales program](https://aibio.space/news/serina-therapeutics-sets-up-13-270-500-market-share-sales-program/) Serina can sell up to $13,270,500 of stock through JonesTrading, which earns up to a 3.0% commission. Its auditor has raised going concern doubt, its lead drug is still preclinical, and the program's size is capped by an SEC float rule. ## Latest Serina Therapeutics news 1. 2024-12-26 Mergers [Serina Therapeutics sells UniverXome to Juvenescence, which takes on $11.2 million of debt](https://aibio.space/news/serina-therapeutics-sells-univerxome-juvenescence-which-takes-11-2/) The unit held the legacy AgeX assets. Juvenescence, Serina's largest holder, paid a nominal cash amount on top of assuming the secured debt. ## Serina Therapeutics at a glance - **Ticker**: SER - **Listing**: AMEX - **Country**: United States - **Cash, Jun 30, 2026**: $23.0 million ### Related companies - [Cardiff Oncology](https://aibio.space/companies/cardiff-oncology/) NASDAQ: CRDF - [Creative Medical Technology Holdings](https://aibio.space/companies/creative-medical-technology/) NASDAQ: CELZ - [Celcuity](https://aibio.space/companies/celcuity/) NASDAQ: CELC - [Organogenesis Holdings](https://aibio.space/companies/organogenesis/) NASDAQ: ORGO - [CervoMed](https://aibio.space/companies/cervomed/) NASDAQ: CRVO - [BioRestorative Therapies](https://aibio.space/companies/biorestorative-therapies/) NASDAQ: BRTX - [Dermata Therapeutics](https://aibio.space/companies/dermata-therapeutics/) NASDAQ: DRMA - [Endovia Health Sciences](https://aibio.space/companies/endovia-health-sciences/) AMEX: EDVA ### Also on AMEX - [OS Therapies](https://aibio.space/companies/os-therapies/) OSTX - [Azitra](https://aibio.space/companies/azitra/) AZTR - [Kairos Pharma](https://aibio.space/companies/kairos-pharma/) KAPA - [Impact BioMedical](https://aibio.space/companies/impact-biomedical/) IBO - [Endovia Health Sciences](https://aibio.space/companies/endovia-health-sciences/) EDVA - [China Pharma Holdings](https://aibio.space/companies/china-pharma/) CPHI ## Serina Therapeutics annual financials | Line | FY2025 | FY2024 | |---|---|---| | Revenue | [$130,000](https://www.sec.gov/Archives/edgar/data/1708599/000170859926000016/) | [$56,000](https://www.sec.gov/Archives/edgar/data/1708599/000170859926000016/) | | Research and development | [$13.2 million](https://www.sec.gov/Archives/edgar/data/1708599/000170859926000016/) | [$7.5 million](https://www.sec.gov/Archives/edgar/data/1708599/000170859926000016/) | | Net income (loss) | [-$19.2 million](https://www.sec.gov/Archives/edgar/data/1708599/000170859926000016/) | [-$11.1 million](https://www.sec.gov/Archives/edgar/data/1708599/000170859926000016/) | | Cash from operations | [-$18.0 million](https://www.sec.gov/Archives/edgar/data/1708599/000170859926000016/) | [-$17.1 million](https://www.sec.gov/Archives/edgar/data/1708599/000170859926000016/) | | Cash and equivalents | [$3.1 million](https://www.sec.gov/Archives/edgar/data/1708599/000170859926000047/) | [$3.7 million](https://www.sec.gov/Archives/edgar/data/1708599/000170859926000016/) | Latest balance sheet, Jun 30, 2026 (10-Q): cash and equivalents $23.0 million. Figures as reported to the SEC in XBRL; each one links to its filing. Not adjusted, not investment advice. ## Questions about Serina Therapeutics Has Serina Therapeutics issued a going-concern warning? Our latest story on this, dated Apr 28, 2025: "Serina Therapeutics sets up $13,270,500 at-the-market share sales program". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/serina-therapeutics-sets-up-13-270-500-market-share-sales-program/). Has Serina Therapeutics raised money recently? Our latest story on this, dated Apr 28, 2025: "Serina Therapeutics sets up $13,270,500 at-the-market share sales program". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/serina-therapeutics-sets-up-13-270-500-market-share-sales-program/). What is the ticker symbol of Serina Therapeutics? Serina Therapeutics, Inc. trades under the ticker SER on AMEX. Where is Serina Therapeutics listed? Serina Therapeutics, Inc. is listed on AMEX. What is the SEC CIK of Serina Therapeutics? The SEC Central Index Key (CIK) for Serina Therapeutics, Inc. is 1708599. Its filings are on SEC EDGAR. How many shares does Serina Therapeutics have outstanding? 25,400,473 shares as of 2026-08-10, per the cover page of its 10-Q filed 2026-08-13. Which country or territory is Serina Therapeutics listed under? Our directory records Serina Therapeutics, Inc. under United States. What does Serina Therapeutics do? Our directory classifies Serina Therapeutics, Inc. as: Biopharma / pharmaceuticals. This is a directory classification, not a description of the pipeline. What is the ISIN of Serina Therapeutics? The ISIN recorded for Serina Therapeutics, Inc. is US81751A1088. Does aibio.space cover Serina Therapeutics? aibio.space lists Serina Therapeutics, Inc. among 2,820 public biotech companies and publishes its news here as stories appear. Where is Serina Therapeutics incorporated? SEC records list its state or country of incorporation as AL. What was Serina Therapeutics's revenue last year? $130,000 for the fiscal year ended Dec 31, 2025, as reported to the SEC. Is Serina Therapeutics profitable? Serina Therapeutics, Inc. reported a net loss of $19.2 million for the fiscal year ended Dec 31, 2025, and used $18.0 million of cash in operations, per its annual report to the SEC. How much does Serina Therapeutics spend on research and development? $13.2 million in the fiscal year ended Dec 31, 2025, per its annual report. How much cash does Serina Therapeutics have? $23.0 million in cash at Jun 30, 2026, per its 10-Q. ## Investor discussion: Serina Therapeutics Members talk about Serina Therapeutics (SER). Reader posts, not aibio.space reporting, and not investment advice. Rules 1. **Securities violations are strictly forbidden.** No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information. 2. **Say whether you hold the stock.** Every post states long, short or no position. 3. **No paid or sponsored posts.** Do not post for anyone who pays or rewards you. 4. **No buy or sell calls and no price targets.** 5. **No accusations of crime or fraud against named people** unless you link a court filing or a regulator's release that makes them. 6. **No personal details and no spam.** No links at all for your first 7 days as a member. Posts that break the rules may be deleted without notice, and the account restricted or closed. See the [terms](https://aibio.space/terms/#discussion) and the [privacy policy](https://aibio.space/privacy/#discussion). ## Capital-markets timeline Financings, listing notices, splits, legal actions and other investor events at Serina Therapeutics, newest first. Each line links the filing it comes from. 1. 2026-08-27 Financings Reported an unregistered sale of its securities. SEC Form 8-K (Items 1.01,3.02,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1708599/000170859926000051/ser-20260821.htm) 2. 2026-03-23 Financings Reported a financing. SEC Form 8-K (Items 1.01,3.02,5.02,5.03,7.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1708599/000170859926000010/ser-20260317xex991_prpipef.htm) 3. 2026-01-15 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01,7.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1708599/000170859926000003/ser-20260109.htm) 4. 2025-09-15 Financings Reported an unregistered sale of its securities. SEC Form 8-K (Items 1.01,2.03,3.02,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1708599/000170859925000110/ser-20250909.htm) 5. 2025-04-28 Financings Reported a financing. SEC Form 424B5. [Source](https://www.sec.gov/Archives/edgar/data/1708599/000162828025020112/serinatherapeutics-atmform.htm) 6. 2025-04-14 Financings Reported a financing. SEC Form 8-K (Items 1.01,3.02,3.03,5.03,7.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1708599/000170859925000042/ser-20250408xex991pronpipe.htm) 7. 2024-12-26 Mergers Reported completing an acquisition or a sale of assets. SEC Form 8-K (Items 1.01,2.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1708599/000170859924000033/ser-20241223.htm) 8. 2024-12-02 Financings Reported an unregistered sale of its securities. SEC Form 8-K (Items 1.01,3.02,8.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1708599/000149315224048316/ex99-1.htm) ## Stock chart Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. [Open AMEX:SER on TradingView](https://www.tradingview.com/symbols/AMEX-SER/). ## SEC filings and registration - **SEC name**: Serina Therapeutics, Inc. - **CIK**: 1708599 - **Industry (SIC)**: Pharmaceutical Preparations (2834) - **US tickers**: SER (NYSE) - **State or country of incorporation**: AL - **Fiscal year ends**: December 31 - **Filer category**: Non-accelerated filer
Smaller reporting company - **Business address**: 601 GENOME WAY, HUNTSVILLE, AL, 35806 - **Phone**: (256) 327-9630 - **Shares outstanding**: 25,400,473 as of 2026-08-10 (10-Q filed 2026-08-13) - **Former names**: AgeX Therapeutics, Inc. ### Recent filings (8-K and 6-K are the company's own announcements) - [8-K](https://www.sec.gov/Archives/edgar/data/1708599/000170859926000060/ser-20261005.htm) filed 2026-10-09 - [8-K](https://www.sec.gov/Archives/edgar/data/1708599/000170859926000054/ser-20260909.htm) filed 2026-09-09 - [8-K](https://www.sec.gov/Archives/edgar/data/1708599/000170859926000051/ser-20260821.htm) filed 2026-08-27 - [S-1](https://www.sec.gov/Archives/edgar/data/1708599/000149315226039910/forms-1.htm) filed 2026-08-24 - [8-K](https://www.sec.gov/Archives/edgar/data/1708599/000170859926000048/ser-20260813.htm) filed 2026-08-13 - [10-Q](https://www.sec.gov/Archives/edgar/data/1708599/000170859926000047/ser-20260630.htm) filed 2026-08-13 - [8-K](https://www.sec.gov/Archives/edgar/data/1708599/000162828026049426/ser-20260719.htm) filed 2026-07-23 - [8-K](https://www.sec.gov/Archives/edgar/data/1708599/000170859926000043/ser-20260723xappointmentof.htm) filed 2026-07-22 Source: [SEC EDGAR](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001708599), retrieved October 23, 2026. Shares outstanding is the cover-page figure from the latest periodic report. The SEC does not publish share prices. ## Listing details Serina Therapeutics, Inc. is a public biotech or pharmaceutical company listed on AMEX under the ticker SER, recorded under United States. The directory classifies it as Biopharma / pharmaceuticals. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them. - **Company**: Serina Therapeutics, Inc. - **Ticker**: SER - **Listing**: AMEX - **Country or territory**: United States - **Business scope**: Biopharma / pharmaceuticals - **ISIN**: US81751A1088 - **Last quote in directory**: 2026-10-21 - **Directory source**: [Listing page](https://www.tradingview.com/symbols/AMEX-SER/) Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. [Tell us about a change](https://aibio.space/reputation/#update). Work at this company? [Claim this page](https://aibio.space/claim/). Published and maintained by aibio.space. Not investment advice. [How we work](https://aibio.space/disclosures/). Who manages this page **This page is managed by aibio.space.** The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. [How we work](https://aibio.space/disclosures/#paid) · [Terms](https://aibio.space/terms/#news) · [Request a correction](https://aibio.space/reputation/#update) --- Source page: https://aibio.space/companies/serina-therapeutics/. Facts in aibio.space stories are checked against company filings and releases; opinion is labelled. Cite as: aibio.space, "Serina Therapeutics (SER) news: going concern and offering", 2026-10-31, https://aibio.space/companies/serina-therapeutics/